Optimal treatment of heart failure (HF) is a continuous challenge. Pharmacological progress, interventional or surgical procedures, kinesio-therapeutic rehabilitation have modestly improved the prognosis of HF with reduced ejection fraction (EF), and patients with HF with preserved EF, or those hospitalized for HF regardless of EF still have a high mortality risk . The 1,2 association to the standard treatment of HF either of CoQ10 (CoQ10) or selenium has been evaluated over the last 30 years in many small and non-statistical powered studies. The recent publication of randomized trials Q-SYMBYO and Kisel-10 renewed interest in these supplements. The article aims to synthesize literature data on the role and mechanism of action of CoQ10 and selenium in HF as well as the results of the published trials and metaanalyses, focusing on the latest. Rezumat Tratamentul optim al insuficien ei cardiace (IC) este o continuă provocare. Progresele farmacologice, procedurile interven ionale sau chirurgicale, reabilitarea kinetoterapeutică au îmbunătă it modest prognosticul IC cu frac ie de ejec ie (FE) scăzută, iar pacien ii cu IC cu FE păstrată sau cei spitaliza i pentru IC indiferent de FE continuă să prezinte un risc de mortalitate crescut . Asocierea la tratamentul standard al insuficien ei cardiace fie a (1,2) coenzimei Q10 (CoQ10), fie a seleniului a fost evaluată în ultimii 30 ani în numeroase studii mici și fără putere statistică. Publicarea recentă a trialurilor randomizate Q-SYMBYO și Kisel-10 a reînnoit interesul pentru aceste suplimente. Articolul își propune să sintetizeze datele din literatură privind rolul și mecanismul de ac iune a CoQ10 și seleniului în IC, precum și rezultatele trial-urilor și meta-analizelor recent publicate. Cuvinte cheie: Coenzima Q10, Seleniu, Insuficien ă cardiacă.
remodelling . Reverse remodelling is ( 3 ) currently defined via surrogate markers as improvement of EF, volumes, cardiac mass, and sphericity index . In an article published (4) in 2015, Gheorghiade et al. highlight the (5) fact that problems in HF are related to the biological anomalies of dysfunctional myocardium: functional alterations in myocytes (mitochondrial, myofibrillar, of s i g n a l l i n g p a t h w a y s o r / a n d c a l c i u m utilization), interstitial, microvascular. The authors propose the redefinition of cardiac reverse remodelling as the improvement of myocyte contractility and of cellular and interstitial characteristics. Therefore, it is important to better understand the biological determinants of cardiac dysfunction and to 5 redirect the therapeutic strategy towards the m y o c y t e , t h e m i c r o c i r c u l a t i o n , t h e interstitium or the metabolic pathways . (3) The primary function of the mitochondrion is to generate the main source of myocyte energy stored in the ATP molecule. In addition to this essential role in cellular metabolism, the mitochondrion is also involved in redox homeostasis; fatty acid and amino acid oxidation; ionic, metabolite and cofactor homeostasis; and heme synthesis . which diffuse through membranes and amplify the oxidative stress . In the (6, 9) "healthy" cell, the antioxidant defence mechanism is present primarily at the mitochondrial level (catalases, peroxidases, aldehyde dehydrogenases), and it is activated concomitantly with the oxidative process.
The negative impact of reactive oxygen species in HF is well-known and consists of that mitochondrial production of reactive oxygen species in HF is high . The source of (10) reactive oxygen species in HF with reduced EF is primarily myocytic , whereas in HF (11) with preserved EF it is endothelial and microvascular . (12) In conclusion, the mitochondrion plays an essential role in providing cellular energy majorly contributing to the generation and metabolism of reactive oxygen species.
Mitochondrial dysfunction determines myocytic, endothelial and musculoskeletal oxidative stress involved in the pathogenesis of heart failure.
Coenzyme Q10
Coenzyme Q10 (Co Q10) or ubiquinone is present in all nucleated cells. It is a lipophilic molecule consisting of a quinone core to which there are 10 isoprenyl groups attached (hence the name of Q10) . It was discovered (13) in 1957 by Fredrik l. Crane . One year later,
Karl Folkers (who discovered and isolated vitamins B6 and B12) published the chemical structure of CoQ10 and during the following (15) years he contributed with more than 300 scientific articles regarding its role. At the beginning of the '70s, together with Gian P Littarru, he described the role of CoQ10 deficiency in HF . In 1978 Peter Mitchell (16, 17, 18) received the Nobel prize in Chemistry for his contribution to the understanding of biological energy transfer, his studies highlighting the essential role of CoQ10 .
The total level of Q10 in the human body is 1 gram distributed primarily in the heart, liver, kidney and pancreas, organs that use a great amount of energy at rest . The major source (15) of CoQ10 is the biosynthesis that involves the (Figure 1 ). It was proved that CoQ10 (21) synthesis is low in HF , in statin-treated (13) patients , and in older people . 
In general, there are few adverse reactions of the administration of CoQ10. An Italian General Reviews study mentioned the presence of 38 ( 3 9 ) adverse reactions in 2664 patients (1.5%) consisting predominantly of nausea (N =30) and allergic rash (N =3). Treatment was discontinued by 9 patients.
There are significant drug interactions with antivitamins K as CoQ10 presents structural 
Conclusions
The approach of a new therapeutic strategy in HF that targets cellular metabolism in the myocardial structure currently represents a There is a need for large studies, adequately designed, with patented products to prove the benefit of this therapeutic approach.
Until then, we cannot ignore the results of the two recent studies mentioned (Q SYMBIO and Ki Sel) that have proven the benefit of long- 
